DPP-IV Inhibitors

Name
DPP-IV Inhibitors
Accession Number
DBCAT002653  (DBCAT001315, DBCAT002433, DBCAT003757)
Description

Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release.

ATC Classification
Drugs
DrugDrug Description
GemigliptinGemigliptin is under investigation in Type 2 Diabetes Mellitus. Gemigliptin has been investigated for the treatment of Cancer and Cisplatin Adverse Reaction.
EvogliptinEvogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2.
GosogliptinGosogliptin has been used in trials studying the treatment of Renal Insufficiency, Chronic.
DutogliptinDutogliptin has been investigated for the treatment of Diabetes Mellitus, Type II.
CarmegliptinCarmegliptin has been used in trials studying the treatment of Diabetes Mellitus Type 2.
BisegliptinInvestigated for use/treatment in diabetes mellitus type 2.
AMG-222Investigated for use/treatment in diabetes mellitus type 2.
TeneligliptinTeneligliptin has been investigated for the treatment of Type 2 Diabetes Mellitus.
OmarigliptinOmarigliptin has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Chronic Renal Insufficiency.
AnagliptinAnagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.
SitagliptinAn oral dipeptidyl peptidase-4 (DPP-4) inhibitor used for the management of type 2 diabetes mellitus.
VildagliptinA once-daily dipeptidyl peptidase 4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus.
AlogliptinA dipeptidyl peptidase-4 (DPP-4) inhibitor used to treat hyperglycemia in patients with type 2 diabetes mellitus.
SaxagliptinAn DPP-4 inhibitor used for the management of type 2 diabetes mellitus.
LinagliptinA dipeptidyl peptidase-4 (DPP-4) inhibitor used to manage hyperglycemia in patients with type 2 diabetes mellitus.
Drugs & Drug Targets
DrugTargetType
GosogliptinDipeptidyl peptidase 4target
DutogliptinDipeptidyl peptidase 4target
BisegliptinDipeptidyl peptidase 4target
AMG-222Dipeptidyl peptidase 4target
SitagliptinDipeptidyl peptidase 4target
SitagliptinCytochrome P450 3A4enzyme
SitagliptinCytochrome P450 2C8enzyme
SitagliptinP-glycoprotein 1transporter
SitagliptinSolute carrier family 22 member 8transporter
VildagliptinDipeptidyl peptidase 4target
AlogliptinDipeptidyl peptidase 4target
AlogliptinCytochrome P450 3A4enzyme
AlogliptinCytochrome P450 2D6enzyme
SaxagliptinDipeptidyl peptidase 4target
SaxagliptinCytochrome P450 3A4enzyme
SaxagliptinCytochrome P450 3A5enzyme
SaxagliptinMultidrug resistance-associated protein 1transporter
SaxagliptinSolute carrier organic anion transporter family member 4C1transporter
SaxagliptinSolute carrier family 22 member 8transporter
LinagliptinDipeptidyl peptidase 4target
LinagliptinCytochrome P450 3A4enzyme
LinagliptinP-glycoprotein 1transporter
LinagliptinSolute carrier family 22 member 1transporter
LinagliptinSolute carrier family 22 member 2transporter
LinagliptinSolute carrier family 22 member 3transporter